e19287 Background: In Colombia, clinical information about EGFR mutated metastatic NSCLC is deficient. The goal of this study is to describe the characteristics and outcomes of a cohort of patients as a real-world evidence from a single institution from Colombia. Methods: This is an observational study of a cohort of patients with EGFR mutated metastatic NSCLC. We did follow up for 52 months and analyzed molecular, clinical and epidemiological characteristics, progression free survival (PFS), overall survival (OSm) and treatment related complications. Results: Sixteen patients were included. 81.2% were female and 18.2% male patients. All patients with ECOG 0-2. Previous smoking history was reported in 31.2%. 25% of the patients had brain metastasis and 18.7% had high volume disease (three or more sites of metastasis). The mutations reported were: 62.5% exon 19 deletion, 31.2% L858R mutation, 0.06% exon 19 insertion, 12.5% truncal T790M mutation. The PFS and the OSm for the whole cohort were 14.6 months and 25 months respectively. As a first line of treatment 25% of the patients received erlotinib (PFS 11.7m and OSm 26.6m), 37.5% gefitinib (PFS 12m and OSm 14.6m), 25% afatinib (PFS 16.6m and OSm has not been reached) and 12.5% osimertinib without progression, during 10.5m of follow up. After 52 months, 50% of the patients had progressed. After the progression, rebiopsy was performed in all patients, T790M mutation was detected in 50%, and 50% of these patients died with OSm of 3m with a fast clinical worsening. In relation with grade 3-4 toxicity it was one case of hepatotoxicity with afatinib, with gefitinib 2/6 patients had diarrhea, with erlotinib one case of hematotoxicity and with osimertinib 1/6 patients developed hepatotoxicity. Conclusions: The clinical characteristics of our cohort was similar to previous reports in the literature. Additionally, molecular behavior was concordant with other reports in Latin America, with a higher incidence of exon 19 deletion. Gefitinib was the most frequent treatment used, probably due to non-availability of other therapies such as afatinib or osimertinib in our country until 2018 and 2019 respectively. There were no differences in PFS or OSm according to anti-EGFR treatment and molecular behavior. The OS was lower than reported in clinical trials in gefitinib treatment group, this finding requires validation in bigger cohort of patients, but is real world data that can partially explain these results.
Read full abstract